Abstract: An organic electroluminescent light source device includes, in the following order from a light-emitting surface side, a first transparent electrode layer, a luminescent layer, a second transparent electrode layer, and a reflecting layer, wherein the reflecting layer includes a concavo-convex structure with an average inclination angle of 12 to 45°. An organic electroluminescent light source device includes, in the following order, a first transparent electrode layer, a luminescent layer, a second transparent electrode layer, a diffusing layer, and a reflecting-scattering layer, wherein the diffusing layer has a concavo-convex surface including a concavo-convex structure with an average inclination angle of 17 to 45°.

Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.

Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.

Abstract: An organic electroluminescent light source device includes, in the following order from a light-emitting surface side, a first transparent electrode layer, a luminescent layer, a second transparent electrode layer, and a reflecting layer, wherein the reflecting layer includes a concavo-convex structure with an average inclination angle of 12 to 45°. An organic electroluminescent light source device includes, in the following order, a first transparent electrode layer, a luminescent layer, a second transparent electrode layer, a diffusing layer, and a reflecting-scattering layer, wherein the diffusing layer has a concavo-convex surface including a concavo-convex structure with an average inclination angle of 17 to 45°.

Abstract: The present invention intends to provide a crosslinkable molded article and a crosslinked molded article free from molding failures, wherein their coefficient of thermal expansion is sufficiently low, their dimensional accuracy is high and a polymerizable composition is sufficiently filled in a fibrous material; a process for producing the same; and a use of such molded articles. A process for producing the molded articles of the present invention is characterized by producing a crosslinkable molded article by performing ring-opening bulk polymerization of a polymerizable composition comprising a cycloolefin monomer, a metathesis catalyst and, in accordance with need, a crosslinking agent and/or a filler in the presence of a glass yarn cloth having a bulk density of 0.50 to 1.10 g/cm3 and, then, if desired, conducting a crosslinking reaction.

Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.

Abstract: The present invention provides a method of detecting/monitoring tumor growth and progression in a tissue by measuring the level of antileukoprotease. Also provided is a method of treating an individual having a tumor by administering antileukoprotease to inhibit the activity of stratum corneum chymotryptic enzyme. Specifically, the tumor is an ovarian carcinoma.

Abstract: The present invention provides a polymerizable composition and a resin formed object capable of providing a crosslinked cycloolefin resin formed object and a crosslinked cycloolefin resin composite excellent in heat resistance, more specifically, a polymerizable composition comprising a cycloolefin mixture containing 0.1 to 50 % by mole of a cycloolefin having, as a substituent group, a monovalent group including an aliphatic carbon-carbon unsaturated bond, a metathesis polymerization catalyst, and a radical generating agent; and formed objects produced by using a polymerizable composition described above which preferably further comprises a chain transfer agent and making the cycloolefin mixture undergo at least ring-opening polymenzation.

Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.

Abstract: The present invention provides a polymerizable composition and a resin formed object capable of providing a crosslinked cycloolefin formed object and a crosslinked cycloolefin resin composite excellent in heat resistance, more specifically, a polymerizable composition comprising a cycloolefin mixture containing 0.1 to 50% by mole of a cycloolefin having, as a substituent group, a monovalent group including an aliphatic carbon-carbon unsaturated bond, a metathesis polymerization catalyst, and a radical generating agent; and formed objects produced by using a polymerizable composition described above which preferably further comprises a chain transfer agent and making the cycloolefin mixture undergo at least ring-opening polymerization.

Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The instant invention also includes a kit containing antibodies for the detection of TADG-15 protein. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.

Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.

Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis. treatment and prevention of cancer particularly breast and ovarian cancer.

Abstract: The present invention provides a method of detecting/monitoring tumor growth and progression in a tissue by measuring the level of antileukoprotease. Also provided is a method of treating an individual having a tumor by administering antileukoprotease to inhibit the activity of stratum corneum chymotryptic enzyme. Specifically, the tumor is an ovarian carcinoma.

Abstract: The present invention provides a method of detecting/monitoring tumor growth and progression in a tissue by measuring the level of antileukoprotease. Also provided is a method of treating an individual having a tumor by administering antileukoprotease to inhibit the activity of stratum corneum chymotryptic enzyme. Specifically, the tumor is an ovarian carcinoma.

Abstract: The present invention provides a DNA encoding a TADG-15 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-15 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-15 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell.

Abstract: A highly polymerizable dicyclopentadiene (DCPD) monomer composition is obtained. The dicyclopentadiene so obtained is highly suitable for ring-opening polymerization by metathesis catalysts. The active DCPD yields articles with excellent physical properties upon in-mold polymerization.

Abstract: Described herein is an oily, transparent reaction product which is prepared by heat treating at 110.degree.-220.degree. C. a dicyclopentadiene and a vinyl aromatic compound. This reaction product can be polymerized by ring-opening in presence or absence of a norbornene monomer to produce a thermoset polymer. Freezing point of the reaction product is below 10.degree. C.

Abstract: A process for producing acetic acid directly from ethylene under mild conditions is provided, wherein ethylene and oxygen are respectively coordinated with the respective transition metals contained in a specified composite catalyst system, and ethylene activated thereby is successively oxidized by two kinds of oxygen complexes contained in the system and having their electric charge states adjusted, the composite catalyst system comprising a complex represented by a formula (MmXn.Ll) and a complex represented by a formula (M'm'Xn'.L'l') wherein is a transition metal of the groups I, IV.about.VII and iron group; X, an anion; L, an organic phosphorus compound as a ligand; M', a transition metal of Pt group; L', a nitrile, organic fluorine compound or organic phosphorus compound as a ligand; m, m', n and n', each a number determined by the valences of the transition metals and anion; and l and l' each the number of ligands.

Abstract: A process for producing an oxygen-containing organic compound by oxidizing olefins under milder conditions is provided, which process comprises oxidizing an olefin activated by its complex formation, in the presence of a platinum group metal complex capable of forming an olefin complex through coordination of the platinum group metal with said olefin, and also in the presence of water, and further oxidizing and regenerating the resulting reduced platinum group metal complex with oxygen coordinated with a transition metal and activated thereby.